Publications dans lesquelles il/elle collabore avec ESTHER CULEBRAS LÓPEZ (51)

2023

  1. Evolution of antibody titers after two doses of mRNA Pfizer-BioNTech vaccine and effect of the third dose in nursing home residents

    PLoS ONE, Vol. 18, Núm. 3 March

  2. High rates of colonization by Staphylococcus aureus in medical students before doing their clinical practices

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 41, Núm. 4, pp. 251-253

2022

  1. Comparison of performance of MALDI-TOF MS and MLST for biotyping carbapenemase-producing Klebsiella pneumoniae sequence types ST11 and ST101 isolates

    Enfermedades infecciosas y microbiologia clinica (English ed.), Vol. 40, Núm. 4, pp. 172-178

  2. Negative effect of the second dose of the BNT162b2 vaccine in a significant percentage of individuals with previous COVID infection

    International Journal of Infectious Diseases, Vol. 114, pp. 85-87

  3. Resistance to fosfomycin is increasing and is significantly associated with extended-spectrum β-lactamase-production in urinary isolates of Escherichia coli

    Medical Microbiology and Immunology, Vol. 211, Núm. 5-6, pp. 269-272

2021

  1. Author Correction: Identification of CRF89_BF, a new member of an HIV-1 circulating BF intersubtype recombinant form family widely spread in South America (Scientific Reports, (2021), 11, 1, (11442), 10.1038/s41598-021-90023-x)

    Scientific Reports

  2. Identification of CRF89_BF, a new member of an HIV-1 circulating BF intersubtype recombinant form family widely spread in South America

    Scientific Reports, Vol. 11, Núm. 1

  3. Service-Learning, Movies, and Infectious Diseases: Implementation of an Active Educational Program in Microbiology as a Tool for Engagement in Social Justice

    Frontiers in Microbiology, Vol. 12

  4. Utilidad de MALDI-TOF y REP-PCR frente a PFGE para el estudio epidemiológico de Acinetobacter baumannii

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 34, Núm. 3, pp. 207-213

2020

  1. Comparison of performance of MALDI-TOF MS and MLST for biotyping carbapenemase-producing Klebsiella pneumoniae sequence types ST11 and ST101 isolates

    Enfermedades Infecciosas y Microbiologia Clinica

  2. Panuveitis and Optic Neuritis as a Possible Initial Presentation of the Novel Coronavirus Disease 2019 (COVID-19)

    Ocular Immunology and Inflammation, Vol. 28, Núm. 6, pp. 922-925

  3. Synergy of linezolid with several antimicrobial agents against linezolid-methicillin-resistant staphylococcal strains

    Antibiotics, Vol. 9, Núm. 8, pp. 1-13

2019

  1. Comparative evaluation of plazomicin MICs obtained using agar dilution versus broth microdilution methods and impact of inoculum size against ESBL-producing Escherichia coli, carbapenemase-producing Klebsiella pneumoniae and methicillin-resistant Staphylococcus aureus clinical isolates

    Diagnostic Microbiology and Infectious Disease, Vol. 95, Núm. 3

  2. Diverse large HIV-1 non-subtype B clusters are spreading among men who have sex with men in Spain

    Frontiers in Microbiology, Vol. 10, Núm. APR

2017

  1. Detection of Escherichia coli ST131 clonal complex (ST705) and Klebsiella pneumoniae ST15 among faecal carriage of extended-spectrum β-lactamase- and carbapenemase-producing enterobacteriaceae

    Journal of Medical Microbiology, Vol. 66, Núm. 2, pp. 169-174

  2. In-vitro activity of several antimicrobial agents against methicillin-resistant Staphylococcus aureus (MRSA) isolates expressing aminoglycoside-modifying enzymes: potency of plazomicin alone and in combination with other agents

    International Journal of Antimicrobial Agents, Vol. 50, Núm. 2, pp. 191-196

  3. Plazomicin activity against 346 extended-spectrum-β-lactamase/AmpC-producing Escherichia coli urinary isolates in relation to aminoglycoside-modifying enzymes

    Antimicrobial Agents and Chemotherapy, Vol. 61, Núm. 2

2016

  1. Compendio de microbiología

    Elsevier

2015

  1. Can plazomicin alone or in combination be a therapeutic option against carbapenem-resistant Acinetobacter baumannii?

    Antimicrobial Agents and Chemotherapy, Vol. 59, Núm. 10, pp. 5959-5966

  2. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains

    International Journal of Antimicrobial Agents